Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
AJ Grossberg, LC Chu, CR Deig… - CA: a cancer journal …, 2020 - Wiley Online Library
Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …
the prognosis for this disease remains very poor, largely because of delayed disease …
An update on treatment options for pancreatic adenocarcinoma
Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
K Nakachi, M Ikeda, M Konishi, S Nomura, H Katayama… - The Lancet, 2023 - thelancet.com
Background S-1 has shown promising efficacy with a mild toxicity profile in patients with
advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 …
advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 …
Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition
M Nagino, S Hirano, H Yoshitomi, T Aoki… - Journal of Hepato …, 2021 - Wiley Online Library
Abstract Background The Japanese Society of Hepato‐Biliary‐Pancreatic Surgery launched
the clinical practice guidelines for the management of biliary tract cancers …
the clinical practice guidelines for the management of biliary tract cancers …
[HTML][HTML] Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with pathologic
features of biliary tract differentiation, and is presumed to arise from the intra-or extrahepatic …
features of biliary tract differentiation, and is presumed to arise from the intra-or extrahepatic …
[HTML][HTML] Addressing the challenges of pancreatic cancer: future directions for improving outcomes
Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …
[HTML][HTML] Intrahepatic cholangiocarcinoma: expert consensus statement
SM Weber, D Ribero, EM O'Reilly, N Kokudo… - Hpb, 2015 - Elsevier
Abstract An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus
meeting of expert panellists met on 15 January 2014 to review current evidence on the …
meeting of expert panellists met on 15 January 2014 to review current evidence on the …
Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy
It remains unclear how obesity worsens treatment outcomes in patients with pancreatic
ductal adenocarcinoma (PDAC). In normal pancreas, obesity promotes inflammation and …
ductal adenocarcinoma (PDAC). In normal pancreas, obesity promotes inflammation and …
[HTML][HTML] Clinical treatment of cholangiocarcinoma: an updated comprehensive review
A Elvevi, A Laffusa, M Scaravaglio, RE Rossi… - Annals of …, 2022 - Elsevier
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and
represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub …
represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub …
[HTML][HTML] How I treat biliary tract cancer
Highlights•Surgical resection remains the mainstay of cure for BTC.•Adjuvant therapy for 6
months with capecitabine is recommended after surgery.•Palliative treatment: CisGem …
months with capecitabine is recommended after surgery.•Palliative treatment: CisGem …